celecoxib has been researched along with Prostatic Hyperplasia in 4 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 9.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia." | 5.13 | Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Prostatic inflammation is the driving force in benign prostatic hyperplasia (BPH)." | 1.91 | Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. ( Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo-El Fetoh, ME | 1 |
| Abdel-Fattah, MM | 1 |
| Mohamed, WR | 1 |
| Ramadan, LAA | 1 |
| Afify, H | 1 |
| Jhang, JF | 1 |
| Jiang, YH | 1 |
| Kuo, HC | 1 |
| Funahashi, Y | 1 |
| O'Malley, KJ | 1 |
| Kawamorita, N | 1 |
| Tyagi, P | 1 |
| DeFranco, DB | 1 |
| Takahashi, R | 1 |
| Gotoh, M | 1 |
| Wang, Z | 1 |
| Yoshimura, N | 1 |
| Falahatkar, S | 1 |
| Mokhtari, G | 1 |
| Pourreza, F | 1 |
| Asgari, SA | 1 |
| Kamran, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 12.0 | 7.70 | -4.31 |
| Study Group | 13.1 | 6.45 | -6.63 |
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 6.06 | 4.01 | -2.05 |
| Study Group | 5.59 | 3.09 | -2.5 |
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 5.54 | 3.45 | -2.09 |
| Study Group | 7.55 | 3.84 | -3.71 |
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 10.0 | 11.9 | 1.9 |
| Study Group | 12.2 | 12.2 | -0.09 |
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 15.2 | 13.5 | -1.70 |
| Study Group | 10.8 | 9.42 | -1.43 |
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 175 | 231 | 55.7 |
| Study Group | 259 | 227 | -32.3 |
2 trials available for celecoxib and Prostatic Hyperplasia
| Article | Year |
|---|---|
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors | 2013 |
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Male; Mi | 2008 |
2 other studies available for celecoxib and Prostatic Hyperplasia
| Article | Year |
|---|---|
Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia.
Topics: ADAM17 Protein; Animals; Celecoxib; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Hyperplasia; Inf | 2023 |
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.
Topics: Androgens; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Mod | 2014 |